Deruxtecan-based antibody-drug conjugate targeting TCR-Vβ2 for the treatment of cutaneous T cell lymphoma
Davis Li
Pro |
Presented at: Society for Investigative Dermatology 2025
Date: 2025-05-07 00:00:00
Views: 35
Summary: Content is hidden. So this is just placeholder text should someone try to view the source of the content. You thought you could get away with it, didn't you? Now look at you just continuing to scroll. Have a great day!